Patients Clinicians About Investor Center FIND A DOCTOR Isoray Announces First Quarter Fiscal 2022 Financial Results Prostate Revenue Increased Year-Over-Year for Second Consecutive Quarter Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed... South Florida Hospital News & Healthcare Report with Chief Research & Development Officer Bill Cavanagh and prominent doctors on treating cancers with Cesium-131 To read the full article below, please use the navigation arrows at the bottom of each page which become visible when you place your cursor at the bottom of each page.... Isoray To Announce First Quarter Fiscal 2022 Financial Results on November 10, 2021 Conference Call is Wednesday, November 10, 2021 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON –October 29, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout... American Brachytherapy Society LDR Prostate Brachytherapy Treatment Consensus Paper Recognizes Isoray’s Cesium-131 RICHLAND, WASHINGTON – September 28, 2021 – The American Brachytherapy Society (ABS) has recognized Isoray’s Cesium-131 in its recently released new consensus statement on the subject of low dose rate (LDR) prostate brachytherapy. This marks the first time Cesium-131... Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options... Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2021 Financial Results Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options... Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021 Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body,... Wall Street Transcript’s In-depth Interview with CEO Lori Woods looks at progress, opportunities and what’s ahead for Isoray To read the full article below, please use the navigation arrows at the bottom of each page which become visible when you place your cursor at the bottom of each page.... Isoray Announces Third Quarter Fiscal 2021 Financial Results Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, WASHINGTON – May 13, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering... Isoray To Announce Third Quarter Fiscal 2021 Financial Results on May 13, 2021 Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – April 29, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today... « Older Entries Categories Blogs Isoray News Events Other Press Releases Quarterly Results Studies Podcast Prostate Brachytherapy Awareness Month Patient Stories Patient Videos Physician Spotlight Prostate News For Media inquiries only, please contact: Sharon Schultz Public and Media Relations (302) 539-3747 schultzpr@mchsi.com Proven • Personalized • Precise Patients & Families Cesium Blu Prostate Cancer Treatment Areas Together Community Doctors & Clinicians Cesium Blu The Data Contact Us Our Products Our company About Us Careers Contact Us Connect with us: Copyright © 2021 Isoray Inc. Terms of Use Privacy Policy Disclosure: The physicians featured on this website may have prior or current relationships with Isoray. These relationships may include, for example: membership on Isoray’s Advisory Board; participation as a clinical investigator in research conducted on Isoray products; provision of consultation or training services; or engagement as a prospective partner in the development of new products. Many of these physicians have received or continue to receive compensation from Isoray in one form or another. The principal nature of a specific physician’s relationship is disclosed on this website adjacent to language featuring that physician. Which of these best describes you? I'm a patient or family member living with cancer. I'm a clinician or doctor. I'm an investor. Other Powered byRightMessage ✕